Myrislignan attenuates lipopolysaccharide-induced inflammation reaction in murine macrophage cells through inhibition of NF-κB signalling pathway activation

Phytotherapy Research

Volumn 26, Issue 9, 2012, Pages 1320-1326

  Jin, Hong ^a,b   Zhu, Zheng Guang ^a,b   Yu, Peng Jiu ^a,b   Wang, Guang Fa ^a,b   Zhang, Jun Yan ^a,b   Li, Jing Rong ^a,b   Ai, Rui Ting ^c   Li, Zhong Huang ^a,b   Tian, Yuan Xin ^a,b   Xu, Wei ^d   Zhang, Jia Jie ^a,b   Wu, Shu Guang ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangdong Key Laboratory for New Drug screening   (China)

^c China National Center for Biotechnology Development   (China)

^d NONE

Author keywords

cyclooxygenase 2; lipopolysaccharide; macrophage; myrislignan; nitric oxide; nuclear factor B

Indexed keywords

CYCLOOXYGENASE 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LIGNAN DERIVATIVE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYRISLIGNAN; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPLASM; CYTOTOXICITY; DRUG STRUCTURE; INHIBITION KINETICS; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUTMEG; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CYCLOOXYGENASE 2; I-KAPPA B PROTEINS; INFLAMMATION; INTERLEUKIN-6; LIGNANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MYRISTICA FRAGRANS;

EID: 84866054761     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3707     Document Type: Article

References (36)

1. Altavilla D, Squadrito F, Bitto A, et al,. 2009. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. Br J Pharmacol 157: 1410-1418.
2. Bauche F, Stephan JP, Touzalin AM, Jegou B,. 1998. In vitro regulation of an inducible-type NO synthase in the rat seminiferous tubule cells. Biol Reprod 58: 431-438.
3. Bogdan C,. 2001. Nitric oxide and the immune response. Nat Immunol 2: 907-916.
4. Chen D, Nie M, Fan MW, Bian Z,. 2008. Anti-inflammatory activity of curcumin in macrophages stimulated by lipopolysaccharides from Porphyromonas gingivalis. Pharmacology 82: 264-269.
5. Cho Y, Kim KH, Shim JS, Hwang JK,. 2008. Inhibitory effects of macelignan isolated from Myristica fragrans HOUTT on melanin biosynthesis. Biol Pharm Bull 31: 986-99.
6. Chung JY, Choo JH, Lee MH, Hwang JK,. 2006. Anticarcinogenic activity of macelignan isolated from Myristica fragrans (nutmeg) against Streptococcus mutans. Phytomedicine 13: 261-6.
7. Cipollone F, Prontera C, Pini B, et al,. 2001. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E (2)-dependent plaque instability. Circulation 104: 921-927.
8. Cui CA, Jin DQ, Hwang YK, et al,. 2008. Macelignan attenuates LPS-induced inflammation and reduces LPS-induced spatial learning impairments in rats. Neurosci Lett 448: 110-4.
9. D'Acquisto F, May MJ, Ghosh S,. 2002. Inhibition of nuclear factor kappa B (NF-κB): an emerging theme in anti-inflammatory therapies. Mol Interv 2: 22-35.
10. Dinarello CA,. 1997. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112: 321S-329S.
11. Dinarello CA,. 2000. Proinflammatory cytokines. Chest 118: 503-508.
12. Filleur F, Le Bail JC, Duroux JL, Simon A, Chulia AJ,. 2001. Antiproliferative, anti-aromatase, anti-17 beta-HSD and antioxidant activities of lignans isolated from Myristica argen tea. Planta Med 67: 700-704.
13. Han KL, Choi JS, Lee JY, et al,., 2008. Therapeutic potential of perox isome proliferators-activate dreceptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes 57: 737-45.
14. Jin DQ, Lim CS, Hwang JK, HaI, Han JS,. 2005. Anti-oxidant and anti-inflammatory activities of macelignan in murine hippocampal cell line and primary culture of rat microglial cells. Biochem Biophys Res Commun 331: 1264-1269.
15. Kamijo R, Harada H, Matsuyama T, et al,. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263: 1612-1615.
16. Kim YW, Zhao RJ, Park SJ, et al,. 2008. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production. Br J Pharmacol 154: 165-173.
17. Kojima F, Kato S, Kawai S,. 2005. Prostaglandin E synthase in the pathophysiology of arthritis. Fundam Clin Pharmacol 19 (3): 255-61.
18. Laskin DL, Pendino KJ,. 1995. Macrophages and inflammatory mediators in tissue injury. Annu Rev Pharmacol Toxicol 35: 655-677.
19. Lawrence T, Willoughby DA, Gilroy DW,. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2: 787-795.
20. Lee TK, Denny EM, Sanghvi JC, et al,. 2009. A noisy paracrine signal determines the cellular NF-kappaB response to lipopolysaccharide. Sci Signal 2 (93): ra 65.
21. Lin WW, Karin M,. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183.
22. Ma J-H, Hwang Y-K, Cho W-H, et al,. 2009. Macelignan attenuates activations of mitogen-activated protein kinases and nuclear factor kappa B induced by lipopolysaccharide in microglial cells. Biol Pharm Bull 32 (6): 1085-1090
23. Medzhitov R, Horng T,. 2009. Transcriptional control of the inflammatory response. Nat Rev Immunol 9: 692-703.
24. Nagy G, Clark JM, Buzas EI, Gorman CL, Cope AP,. 2007. Nitric oxide, chronic inflammation and autoimmunity. Immunol Lett 111: 1-5.
25. Nguyen PH, van Thu Le T, Kang HW, et al,. 2010. AMP-activated protein kinase (AMPK) activators from Myristica fragrans (nutmeg) and their anti-obesity effect. Bioorg Mel Chem Lett 20: 4128-4131.
26. Ozaki Y, Soedigdo S, Wattimena YR, Suganda AG,. 1989. Antiinflammatory effect of mace, aril of Myristica fragrans HOUTT., and its active principles. Jpn J Pharmacol 49: 155-163.
27. Pahl HL,. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866.
28. Pope RM, Tschopp J,. 2007. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56: 3183-3188.
29. Checker R, Chatterjee S, Sharma D, et al,. 2008. Immunomodulatory and radioprotective effects of lignans derived from fresh nutmeg mace (Myristica fragrans) in mammalian splenocytes. Int Immunopharmacol 8: 661-669.
30. Sadhu SK, Okuyama E, Fujimoto H, Ishibashi M,. 2003. Separation of Leucasaspera, a medicinal plant of Bangladesh, guided by prostaglandin inhibitory and anti-oxidantactivities. Chem Pharm Bull 51: 595-598.
31. Sethi G, Tergaonkar V,. 2009. Potential pharmacological control of the NF-kappaB pathway. Trends Pharmacol Sci 30: 313-321.
32. Sohn JH, Han KL, Choo JH, Hwang JK,. 2007. Macelignan protects HepG2 cells against tert-butylhydroperoxide-induced oxidative damage. Biofactors 29: 1-10.
33. Tracey KJ,. 2002. The inflammatory reflex. Nature 420: 853-859.
34. Tripathi P, Tripathi P, Kashyap L, Singh V,. 2007. The role of nitric oxide in inflammatory reactions. FEMS Immunol Med Microbiol 51: 443-452.
35. Yamamoto Y, Gaynor RB,. 2001. Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142.
36. Yan J, Greer JM,. 2008. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol Disord Drug Targets 7: 536-557.